Targeting dendritic cells with biomaterials: developing the next generation of vaccines

Sai T. Reddy, Melody A. Swartz, Jeffrey A. Hubbell

Research output: Contribution to journalArticle

304 Citations (Scopus)

Abstract

Current vaccine and immunotherapy technology faces ongoing challenges in both efficacy and practicality: many chronic diseases cannot yet be addressed by vaccination, and several vaccines that do function well require multiple injections, which is a substantial limitation in various parts of the world. A possible key to developing the next generation of vaccines is the ability to deliver antigen to dendritic cells (DCs) more specifically and induce the subsequent activation of T-cell immunity. However, antigen delivery to, and activation of, DCs is a complex problem, involving antigen transport to DC-rich areas, DC binding and antigen uptake, and antigen processing and presentation. Addressing these challenges requires novel and multidisciplinary approaches, for example, the application of biomaterials to immunotechnology. Here, we review the latest advances in biomaterial drug vehicles, such as polymer microparticles and nanoparticles, and liposomes, that are being used to target DCs in new strategies for vaccination.

Original languageEnglish
Pages (from-to)573-579
Number of pages7
JournalTrends in Immunology
Volume27
Issue number12
DOIs
StatePublished - Dec 1 2006
Externally publishedYes

Fingerprint

Biocompatible Materials
Dendritic Cells
Vaccines
Antigens
Antigen Presentation
Vaccination
Liposomes
Immunotherapy
Nanoparticles
Immunity
Polymers
Chronic Disease
Technology
T-Lymphocytes
Injections
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Targeting dendritic cells with biomaterials : developing the next generation of vaccines. / Reddy, Sai T.; Swartz, Melody A.; Hubbell, Jeffrey A.

In: Trends in Immunology, Vol. 27, No. 12, 01.12.2006, p. 573-579.

Research output: Contribution to journalArticle

Reddy, Sai T. ; Swartz, Melody A. ; Hubbell, Jeffrey A. / Targeting dendritic cells with biomaterials : developing the next generation of vaccines. In: Trends in Immunology. 2006 ; Vol. 27, No. 12. pp. 573-579.
@article{a4c4610084f242fb9aae8b93f1728f5f,
title = "Targeting dendritic cells with biomaterials: developing the next generation of vaccines",
abstract = "Current vaccine and immunotherapy technology faces ongoing challenges in both efficacy and practicality: many chronic diseases cannot yet be addressed by vaccination, and several vaccines that do function well require multiple injections, which is a substantial limitation in various parts of the world. A possible key to developing the next generation of vaccines is the ability to deliver antigen to dendritic cells (DCs) more specifically and induce the subsequent activation of T-cell immunity. However, antigen delivery to, and activation of, DCs is a complex problem, involving antigen transport to DC-rich areas, DC binding and antigen uptake, and antigen processing and presentation. Addressing these challenges requires novel and multidisciplinary approaches, for example, the application of biomaterials to immunotechnology. Here, we review the latest advances in biomaterial drug vehicles, such as polymer microparticles and nanoparticles, and liposomes, that are being used to target DCs in new strategies for vaccination.",
author = "Reddy, {Sai T.} and Swartz, {Melody A.} and Hubbell, {Jeffrey A.}",
year = "2006",
month = "12",
day = "1",
doi = "10.1016/j.it.2006.10.005",
language = "English",
volume = "27",
pages = "573--579",
journal = "Trends in Immunology",
issn = "1471-4906",
publisher = "Elsevier Limited",
number = "12",

}

TY - JOUR

T1 - Targeting dendritic cells with biomaterials

T2 - developing the next generation of vaccines

AU - Reddy, Sai T.

AU - Swartz, Melody A.

AU - Hubbell, Jeffrey A.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Current vaccine and immunotherapy technology faces ongoing challenges in both efficacy and practicality: many chronic diseases cannot yet be addressed by vaccination, and several vaccines that do function well require multiple injections, which is a substantial limitation in various parts of the world. A possible key to developing the next generation of vaccines is the ability to deliver antigen to dendritic cells (DCs) more specifically and induce the subsequent activation of T-cell immunity. However, antigen delivery to, and activation of, DCs is a complex problem, involving antigen transport to DC-rich areas, DC binding and antigen uptake, and antigen processing and presentation. Addressing these challenges requires novel and multidisciplinary approaches, for example, the application of biomaterials to immunotechnology. Here, we review the latest advances in biomaterial drug vehicles, such as polymer microparticles and nanoparticles, and liposomes, that are being used to target DCs in new strategies for vaccination.

AB - Current vaccine and immunotherapy technology faces ongoing challenges in both efficacy and practicality: many chronic diseases cannot yet be addressed by vaccination, and several vaccines that do function well require multiple injections, which is a substantial limitation in various parts of the world. A possible key to developing the next generation of vaccines is the ability to deliver antigen to dendritic cells (DCs) more specifically and induce the subsequent activation of T-cell immunity. However, antigen delivery to, and activation of, DCs is a complex problem, involving antigen transport to DC-rich areas, DC binding and antigen uptake, and antigen processing and presentation. Addressing these challenges requires novel and multidisciplinary approaches, for example, the application of biomaterials to immunotechnology. Here, we review the latest advances in biomaterial drug vehicles, such as polymer microparticles and nanoparticles, and liposomes, that are being used to target DCs in new strategies for vaccination.

UR - http://www.scopus.com/inward/record.url?scp=33750728433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750728433&partnerID=8YFLogxK

U2 - 10.1016/j.it.2006.10.005

DO - 10.1016/j.it.2006.10.005

M3 - Article

C2 - 17049307

AN - SCOPUS:33750728433

VL - 27

SP - 573

EP - 579

JO - Trends in Immunology

JF - Trends in Immunology

SN - 1471-4906

IS - 12

ER -